Mr. Timothy Ko reports

ENTHEON BIOMEDICAL ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING

Further to its news releases dated Dec. 2, 2024, and Dec. 24, 2024, Entheon Biomedical Corp. has closed a non-brokered private placement for total gross proceeds of $500,000.

The company has allotted and issued five million units at a price of 10 cents per unit. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant entitling the holder to acquire one additional common share at an exercise price of 15 cents for a period of 24 months from the date of issuance.

The company will use the proceeds from the placement toward general working capital purposes. All securities issued under the placement are subject to a hold period of four months and one day expiring on May 4, 2025.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

We seek Safe Harbor.